Caris Life Sciences Inc.
CAI | NASDAQ
$32.77
-$1.56 (-4.54%)
Nov 2, 2026, 12:17 PM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q3 2021 Sep 30, 2021 | Q2 2021 Jun 30, 2021 | Q1 2021 Mar 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 989.61M | 907.29M | 812.03M | 649.06M | 533.85M | 452.5M | 412.26M | 282.35M | 180.73M | 80.68M | 331.64M | 309.87M | 299.9M |
Cost of Revenue | 300.24M | 283.84M | 272.86M | 260.11M | 247.99M | 242.77M | 233.48M | 174.27M | 117.06M | 54.56M | 112.49M | 96.17M | 125.02M |
Gross Profit | 689.36M | 623.45M | 539.17M | 388.96M | 285.86M | 209.73M | 178.78M | 108.08M | 63.67M | 26.11M | 219.16M | 213.69M | 174.88M |
Operating Income | 153.26M | 144.32M | 81.09M | -44.37M | -137.85M | -88.83M | -123.1M | -86.06M | -25.21M | -92.23M | 202.11M | 171.22M | 153.39M |
Interest Income | 28.03M | 22.83M | 16.5M | 10.45M | 4.84M | 5.86M | 7.12M | 6.15M | 4.41M | 1.77M | n/a | n/a | n/a |
Pretax Income | 105.02M | 33.85M | -68.09M | -186.99M | -279.05M | -273.44M | -281.89M | -244.94M | -177.21M | -111.03M | 148.45M | 110.41M | 71.1M |
Net Income | 105.14M | 33.98M | -68.09M | -186.99M | -279.05M | -273.44M | -281.89M | -244.94M | -177.21M | -111.03M | 139.08M | 103.37M | 64.8M |
Selling & General & Admin | 418.96M | 405.28M | 392.47M | 372.45M | 356.82M | 329.97M | 321.99M | 241.35M | 163.74M | 83.96M | 34.92M | 35.7M | 39.4M |
Research & Development | 91.2M | 83.89M | 101.58M | 96.85M | 102.87M | 102.61M | 113.92M | 86.81M | 59.16M | 34.38M | n/a | n/a | n/a |
Other Expenses | 25.94M | -10.04M | -35.98M | -35.98M | -35.98M | -134.02M | -134.02M | -134.02M | -134.02M | n/a | 24.69M | 24.69M | n/a |
Operating Expenses | 536.1M | 479.13M | 458.08M | 433.32M | 423.71M | 298.56M | 301.88M | 194.14M | 88.88M | 118.34M | 59.61M | 60.39M | 39.4M |
Interest Expense | 46.9M | 56.88M | 56.85M | 58.76M | 59.05M | 53.52M | 50.03M | 36.76M | 22.96M | 9.29M | 29.25M | 45.88M | 52.36M |
Selling & Marketing Expenses | 184.23M | 172.72M | 166.26M | 122.11M | 117.6M | 114.05M | 113.96M | 113.96M | 77.2M | 38.49M | -1.15M | 5.54M | 12.01M |
Cost & Expenses | 836.34M | 762.97M | 730.94M | 693.43M | 671.7M | 541.33M | 535.36M | 368.4M | 205.94M | 172.9M | 172.1M | 156.57M | 164.42M |
Income Tax Expense | -111K | -134K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 10.43M | 8.1M | 7.36M |
Shares Outstanding (Basic) | 282.89M | 282.56M | 282.33M | 282.1M | 268.44M | 254.79M | 281.09M | 281.09M | 254.79M | 254.79M | 17.34M | 17.28M | 17.27M |
Shares Outstanding (Diluted) | 282.89M | 282.56M | 289.89M | 297.21M | 276M | 254.79M | 281.09M | 281.09M | 254.79M | 254.79M | 17.53M | 17.48M | 17.52M |
EPS (Basic) | 0.37 | -1.56 | -1.95 | -2.46 | -2.88 | -1.30 | -1.43 | -1.21 | -0.88 | -0.53 | 7.89 | 5.82 | 3.71 |
EPS (Diluted) | 0.36 | -1.51 | -1.91 | -2.41 | -2.82 | -1.30 | -1.43 | -1.21 | -0.88 | -0.53 | 7.79 | 5.74 | 3.66 |
EBITDA | 172.69M | 111.36M | 11.38M | -114.21M | -207.22M | -201.95M | -203.23M | -175.25M | -124.94M | -84.03M | 297.02M | 274.87M | 287.2M |
EBIT | 151.92M | 90.73M | -11.24M | -141.6M | -240.27M | -240.2M | -252.14M | -215.09M | -154.25M | -101.74M | 156.81M | 191.75M | 175.5M |
Depreciation & Amortization | 20.76M | 20.64M | 22.62M | 27.39M | 33.05M | 38.25M | 48.91M | 39.85M | 29.32M | 17.71M | 85.38M | 83.12M | 111.7M |
Add to Watchlist
Select watchlists to add or remove CAI